Exact Mass: 409.2439

Exact Mass Matches: 409.2439

Found 276 metabolites which its exact mass value is equals to given mass value 409.2439, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Acidissiminol epoxide

N-[2-(4-{[(2E)-5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidate

C25H31NO4 (409.2253)


Acidissiminol epoxide is found in beverages. Acidissiminol epoxide is an alkaloid from fruits of Limonia acidissima (wood apple). Alkaloid from fruits of Limonia acidissima (wood apple). Acidissiminol epoxide is found in beverages and fruits.

   

(3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine

3-[(14-carboxytetradeca-3,5,11-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


(3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (3E,5Z,11Z)-pentadeca-3,5,11-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-9,11,13-trienedioylcarnitine

3-[(14-carboxytetradeca-9,11,13-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-9,11,13-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-9,11,13-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-9,11,13-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-9,11,13-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-3,6,9-trienedioylcarnitine

3-[(14-carboxytetradeca-3,6,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-3,6,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-3,6,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-3,6,9-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-3,6,9-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-7,10,13-trienedioylcarnitine

3-[(14-carboxytetradeca-7,10,13-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-7,10,13-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-7,10,13-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-7,10,13-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-7,10,13-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-4,6,8-trienedioylcarnitine

3-[(14-carboxytetradeca-4,6,8-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-4,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-4,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-4,6,8-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-4,6,8-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-5,8,11-trienedioylcarnitine

3-[(14-Carboxytetradeca-5,8,11-trienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C22H35NO6 (409.2464)


Pentadeca-5,8,11-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-5,8,11-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-5,8,11-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-5,8,11-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine

3-[(14-carboxytetradeca-2,6,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


(2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,10E)-pentadeca-2,6,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-5,7,9-trienedioylcarnitine

3-[(14-carboxytetradeca-5,7,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-5,7,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-5,7,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-5,7,9-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-5,7,9-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pentadeca-3,5,7-trienedioylcarnitine

3-[(14-carboxytetradeca-3,5,7-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H35NO6 (409.2464)


Pentadeca-3,5,7-trienedioylcarnitine is an acylcarnitine. More specifically, it is an pentadeca-3,5,7-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pentadeca-3,5,7-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Pentadeca-3,5,7-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

3-{[5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

3-{[6-(5-hexylfuran-2-yl)hexanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


6-(5-hexylfuran-2-yl)hexanoylcarnitine is an acylcarnitine. More specifically, it is an 6-(5-hexylfuran-2-yl)hexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-(5-hexylfuran-2-yl)hexanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-(5-hexylfuran-2-yl)hexanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

3-{[7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

3-{[7-(5-pentylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


7-(5-pentylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(5-pentylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(5-pentylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(5-pentylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-(5-Butylfuran-2-yl)octanoylcarnitine

3-{[8-(5-butylfuran-2-yl)octanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


8-(5-Butylfuran-2-yl)octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-(5-butylfuran-2-yl)octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-(5-Butylfuran-2-yl)octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-(5-Butylfuran-2-yl)octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Linoleoyl Glutamic acid

2-[(1-Hydroxyoctadeca-9,12-dien-1-ylidene)amino]pentanedioate

C23H39NO5 (409.2828)


N-linoleoyl glutamic acid, also known as N-linoleoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

2-({4-[5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl}amino)ethan-1-ol

2-({4-[5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl}amino)ethan-1-ol

C23H27N3O4 (409.2001)


   

3-N-Methylspiperone

8-[4-(4-fluorophenyl)-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one

C24H28FN3O2 (409.2165)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

Anthra(1,9-cd)pyrazol-6(2H)-one, 2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)-

14-{2-[(2-hydroxyethyl)amino]ethyl}-10-({2-[(2-hydroxyethyl)amino]ethyl}amino)-14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9,11,13(16)-heptaen-8-one

C22H27N5O3 (409.2114)


   

Butaperazine

1-{10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazin-2-yl}butan-1-one

C24H31N3OS (409.2188)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist

   

2-Ethyl-5,7-dimethyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine

5-{2-[4-({2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)phenyl]phenyl}-2H-1,2,3,4-tetrazole

C24H23N7 (409.2015)


D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D057911 - Angiotensin Receptor Antagonists

   

2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid

2-methyl-2-[4-(3-{1-[(4-methylphenyl)methyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl}propyl)phenoxy]propanoic acid

C23H27N3O4 (409.2001)


   

Met-leu-phe

2-{2-[2-amino-4-(methylsulfanyl)butanamido]-4-methylpentanamido}-3-phenylpropanoic acid

C20H31N3O4S (409.2035)


   

Methyl (2E)-2-(10,13-dimethyl-11-oxo-3-pyrrolidin-1-yl-2,7,8,9,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-ylidene)acetate

Methyl (2E)-2-(10,13-dimethyl-11-oxo-3-pyrrolidin-1-yl-2,7,8,9,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-ylidene)acetic acid

C26H35NO3 (409.2617)


   
   

Malyngamide V

Malyngamide V

C23H39NO5 (409.2828)


   

isariotin C

isariotin C

C21H31NO7 (409.21)


   
   

Malyngamide W

Malyngamide W

C23H39NO5 (409.2828)


   

Dimethyl dicitrinin A

Dimethyl dicitrinin A

C25H29O5 (409.2015)


   
   
   

marineosin B

marineosin B

C25H35N3O2 (409.2729)


A macrocycle isolated from a marine sediment-derived actinomycete, Streptomyces sp. A stereoisomer of marineosin A, it exhibits cytotoxicity against colon tumour cell lines.

   

7-Angelylheliotrin

7-Angelylheliotrin

C22H35NO6 (409.2464)


   
   

haterumaimide P

haterumaimide P

C22H32ClNO4 (409.202)


   

brevicompanine H

brevicompanine H

C24H31N3O3 (409.2365)


   

callosine

callosine

C21H31NO7 (409.21)


   
   
   

1-demethylwinkleridine

1-demethylwinkleridine

C22H35NO6 (409.2464)


   

Lapaconidin|Lappaconidin

Lapaconidin|Lappaconidin

C22H35NO6 (409.2464)


   

cochinchistemonine

cochinchistemonine

C22H35NO6 (409.2464)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Laxiracemosin H

3-[(5R,9R,10R,13S,14S,17R)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]pyrrole-2,5-dione

C26H35NO3 (409.2617)


Laxiracemosin H is a terpene alkaloid with a tirucallane skeleton isolated from Dysoxylum lenticellatum. It has a role as a metabolite and a plant metabolite. It is a terpene alkaloid, a tetracyclic triterpenoid, a cyclic terpene ketone and a member of maleimides. A terpene alkaloid with a tirucallane skeleton isolated from Dysoxylum lenticellatum.

   

Marineosin A

Marineosin A

C25H35N3O2 (409.2729)


A macrocycle isolated from a marine sediment-derived actinomycete, Streptomyces sp. It exhibits cytotoxicity against colon tumour cell lines.

   

FR130739

FR130739

C24H23N7 (409.2015)


CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4150; ORIGINAL_PRECURSOR_SCAN_NO 4149 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4178; ORIGINAL_PRECURSOR_SCAN_NO 4174 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4165; ORIGINAL_PRECURSOR_SCAN_NO 4164 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4170; ORIGINAL_PRECURSOR_SCAN_NO 4169 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4179; ORIGINAL_PRECURSOR_SCAN_NO 4177 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4181; ORIGINAL_PRECURSOR_SCAN_NO 4177 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8688; ORIGINAL_PRECURSOR_SCAN_NO 8686 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8687; ORIGINAL_PRECURSOR_SCAN_NO 8683 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8694; ORIGINAL_PRECURSOR_SCAN_NO 8692 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8713; ORIGINAL_PRECURSOR_SCAN_NO 8711 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8719; ORIGINAL_PRECURSOR_SCAN_NO 8716 CONFIDENCE standard compound; INTERNAL_ID 1233; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8718; ORIGINAL_PRECURSOR_SCAN_NO 8716

   

Meptazinol glucuronide

Meptazinol glucuronide

C21H31NO7 (409.21)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

METHIONYL-LEUCYLPHENYLALANINE

METHIONYL-LEUCYLPHENYLALANINE

C20H31N3O4S (409.2035)


   

Severin

N-[2-(4-{[(2E)-5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzamide

C25H31NO4 (409.2253)


   

IsoLG-Etn

15-isoLG hydroxylactam-ethanolamine

C22H35NO6 (409.2464)


   

NA 23:4;O4

N-(9Z,12Z-octadecadienoyl)-glutamic acid

C23H39NO5 (409.2828)


   
   

Milipertine

Milipertine

C24H31N3O3 (409.2365)


C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

   

4-(N-Boc-phenylaminomethyl)benzeneboronic acid pinacol ester

4-(N-Boc-phenylaminomethyl)benzeneboronic acid pinacol ester

C24H32BNO4 (409.2424)


   

4-dodecyl-4-ethylmorpholinium ethyl sulphate

4-dodecyl-4-ethylmorpholinium ethyl sulphate

C20H43NO5S (409.2862)


   

(R)-(-)-GLYCIDYLPHTHALIMIDE

(R)-(-)-GLYCIDYLPHTHALIMIDE

C23H27N3O4 (409.2001)


   
   

chempacific 36181

chempacific 36181

C23H39NO3S (409.2651)


   
   

n-Butyl methacrylate, acrylonitrile, n-butyl acrylate, methacrylic acid polymer

n-Butyl methacrylate, acrylonitrile, n-butyl acrylate, methacrylic acid polymer

C22H35NO6 (409.2464)


   

(S)-2-[Diphenyl[[trisisopropylsilyl]oxy]methyl]pyrrolidine

(S)-2-[Diphenyl[[trisisopropylsilyl]oxy]methyl]pyrrolidine

C26H39NOSi (409.2801)


   

(R,E)-ethyl 5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoate

(R,E)-ethyl 5-([1,1-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoate

C25H31NO4 (409.2253)


   

(S)-N-Fmoc-Octylglycine

(S)-N-Fmoc-Octylglycine

C25H31NO4 (409.2253)


   

5-[3-(tert-butyl)-1-(3-methylbenzyl)-1h-pyrazol-5-yl]-4-cyclohexyl-4h-1,2,4-triazole-3-thiol

5-[3-(tert-butyl)-1-(3-methylbenzyl)-1h-pyrazol-5-yl]-4-cyclohexyl-4h-1,2,4-triazole-3-thiol

C23H31N5S (409.23)


   

(R)-N-Fmoc-Octylglycine

(R)-N-Fmoc-Octylglycine

C25H31NO4 (409.2253)


   

Benexate

benzyl 2-[4-[(diaminomethylideneamino)methyl]cyclohexanecarbonyl]oxybenzoate

C23H27N3O4 (409.2001)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

1-[2-[BIS(4-FLUOROPHENYL)METHOXY]ETHYL]-4-(PYRIDINYL)-PIPERAZINE

1-[2-[BIS(4-FLUOROPHENYL)METHOXY]ETHYL]-4-(PYRIDINYL)-PIPERAZINE

C24H25F2N3O (409.1966)


   

3,5-BIS(4-TERT-BUTYLPHENYL)-4-PHENYL-4H&

3,5-BIS(4-TERT-BUTYLPHENYL)-4-PHENYL-4H&

C28H31N3 (409.2518)


   

Onalespib

Onalespib

C24H31N3O3 (409.2365)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor

   

Zuranolone

Zuranolone

C25H35N3O2 (409.2729)


C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

   

Glutamic acid linoleamide

Glutamic acid linoleamide

C23H39NO5 (409.2828)


   

Methionyl-leucyl-phenylalanine

Methionyl-leucyl-phenylalanine

C20H31N3O4S (409.2035)


   
   
   

L-Methionyl-L-phenylalanyl-L-leucine

L-Methionyl-L-phenylalanyl-L-leucine

C20H31N3O4S (409.2035)


   

FK-739 free acid

FK-739 free acid

C24H23N7 (409.2015)


   

Butaperazine

Butaperazine

C24H31N3OS (409.2188)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist

   

4-formyl-3-hydroxy-8a-methyl-6-(4-methylpent-3-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

4-formyl-3-hydroxy-8a-methyl-6-(4-methylpent-3-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

C25H29O5- (409.2015)


   

4-formyl-3-hydroxy-6,8a-dimethyl-5-(3-methylbut-2-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

4-formyl-3-hydroxy-6,8a-dimethyl-5-(3-methylbut-2-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

C25H29O5- (409.2015)


   

4-formyl-3-hydroxy-8a-methyl-7-(4-methylpent-3-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

4-formyl-3-hydroxy-8a-methyl-7-(4-methylpent-3-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

C25H29O5- (409.2015)


   

4-formyl-3-hydroxy-7,8a-dimethyl-8-(3-methylbut-2-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

4-formyl-3-hydroxy-7,8a-dimethyl-8-(3-methylbut-2-enyl)-9,10-dioxo-1-propan-2-yl-8,10a-dihydro-5H-anthracen-2-olate

C25H29O5- (409.2015)


   

(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-3-[[(3S)-3-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]-3,6-dihydro-2H-pyran-2-carboxylate

(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-3-[[(3S)-3-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]-3,6-dihydro-2H-pyran-2-carboxylate

C16H25N8O5+ (409.1948)


   

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

C23H39NO5 (409.2828)


   

8-(5-Butylfuran-2-yl)octanoylcarnitine

8-(5-Butylfuran-2-yl)octanoylcarnitine

C23H39NO5 (409.2828)


   

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

C23H39NO5 (409.2828)


   

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

C23H39NO5 (409.2828)


   

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

C23H39NO5 (409.2828)


   

N-Linoleoyl Glutamic acid

N-Linoleoyl Glutamic acid

C23H39NO5 (409.2828)


   

methyl (17Z)-11-oxo-3-(1-pyrrolidinyl)pregna-3,5,17-trien-21-oate

methyl (17Z)-11-oxo-3-(1-pyrrolidinyl)pregna-3,5,17-trien-21-oate

C26H35NO3 (409.2617)


   

Pentadeca-3,6,9-trienedioylcarnitine

Pentadeca-3,6,9-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-4,6,8-trienedioylcarnitine

Pentadeca-4,6,8-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-5,7,9-trienedioylcarnitine

Pentadeca-5,7,9-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-3,5,7-trienedioylcarnitine

Pentadeca-3,5,7-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-5,8,11-trienedioylcarnitine

Pentadeca-5,8,11-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-9,11,13-trienedioylcarnitine

Pentadeca-9,11,13-trienedioylcarnitine

C22H35NO6 (409.2464)


   

Pentadeca-7,10,13-trienedioylcarnitine

Pentadeca-7,10,13-trienedioylcarnitine

C22H35NO6 (409.2464)


   

(3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine

(3E,5Z,11Z)-Pentadeca-3,5,11-trienedioylcarnitine

C22H35NO6 (409.2464)


   

(2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine

(2E,6E,10E)-Pentadeca-2,6,10-trienedioylcarnitine

C22H35NO6 (409.2464)


   

(3S,4aR,6aR,12aR,12bS)-3-Hydroxy-4,4,6a,12b-tetramethyl-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydrobenzo[f]pyrano[4,3-b]chromen-11(2H)-one

(3S,4aR,6aR,12aR,12bS)-3-Hydroxy-4,4,6a,12b-tetramethyl-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydrobenzo[f]pyrano[4,3-b]chromen-11(2H)-one

C25H31NO4 (409.2253)


   
   

N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(5-methyl-2-propan-2-ylphenoxy)acetamide

N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(5-methyl-2-propan-2-ylphenoxy)acetamide

C24H31N3O3 (409.2365)


   

N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide

N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide

C24H31N3O3 (409.2365)


   

(5R)-5-tert-butyl-1-[(3S)-3-[(4-methylphenyl)thio]-3-phenylpropyl]-2-azepanone

(5R)-5-tert-butyl-1-[(3S)-3-[(4-methylphenyl)thio]-3-phenylpropyl]-2-azepanone

C26H35NOS (409.2439)


   

7-cyclohexyl-3-(4-morpholinyl)-1-(1-piperidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

7-cyclohexyl-3-(4-morpholinyl)-1-(1-piperidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

C24H35N5O (409.2841)


   

1-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide

1-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide

C24H31N3O3 (409.2365)


   

1alpha,16beta-Dimethoxy-4-(methoxymethyl)aconitane-6alpha,8,14alpha-triol

1alpha,16beta-Dimethoxy-4-(methoxymethyl)aconitane-6alpha,8,14alpha-triol

C22H35NO6 (409.2464)


   

(2S)-2-{[(9Z)-octadec-9-enoyl]amino}pentanedioate

(2S)-2-{[(9Z)-octadec-9-enoyl]amino}pentanedioate

C23H39NO5-2 (409.2828)


   
   
   
   

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[(2-pyridin-2-ylacetyl)amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

(2S)-2-[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2S)-2-[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2S)-2-[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C23H27N3O4 (409.2001)


   

[(1S)-1-[(4-fluorophenyl)methyl]-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol

[(1S)-1-[(4-fluorophenyl)methyl]-7-methoxy-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C24H28FN3O2 (409.2165)


   

(3aR,4S,9bS)-8-(1-cyclohexenyl)-N-cyclopentyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

(3aR,4S,9bS)-8-(1-cyclohexenyl)-N-cyclopentyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C25H35N3O2 (409.2729)


   

(6S,7R,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6S,7R,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(6R,7R,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7R,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(2R,3S)-8-(2-benzofuranyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-(2-benzofuranyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H27N3O4 (409.2001)


   

(2R)-2-[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2R)-2-[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2R)-2-[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2S)-2-[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

(2R)-2-[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C20H31N3O4S (409.2035)


   

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[1-oxo-2-(2-pyridinyl)ethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C23H27N3O4 (409.2001)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]urea

C19H31N5O5 (409.2325)


   

N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide

C19H31N5O5 (409.2325)


   

(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C23H27N3O4 (409.2001)


   

(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C23H27N3O4 (409.2001)


   

(1S,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1S,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-N-propan-2-yl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C23H27N3O4 (409.2001)


   

(3aS,4R,9bR)-8-(1-cyclohexenyl)-N-cyclopentyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

(3aS,4R,9bR)-8-(1-cyclohexenyl)-N-cyclopentyl-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C25H35N3O2 (409.2729)


   

(6R,7S,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7S,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(6S,7R,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6S,7R,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(6R,7R,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7R,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(6S,7S,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6S,7S,8S)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   

(6R,7S,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7S,8R)-N-cyclopentyl-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C24H31N3O3 (409.2365)


   
   
   
   
   
   
   
   

3-((2E,6E)-9-((S)-3,3-Dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-yl)-4-hydroxy-6-(pyridin-3-yl)-2H-pyran-2-one

3-((2E,6E)-9-((S)-3,3-Dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-yl)-4-hydroxy-6-(pyridin-3-yl)-2H-pyran-2-one

C25H31NO4 (409.2253)


   

(2S,3S,3aR,9bR)-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-7-[(E)-prop-1-enyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-7-[(E)-prop-1-enyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C23H27N3O4 (409.2001)


   

(2R,3R,3aS,9bS)-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-7-[(E)-prop-1-enyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-7-[(E)-prop-1-enyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C23H27N3O4 (409.2001)


   

Fucalpha1-2FucalphaO[CH2]6NH2

Fucalpha1-2FucalphaO[CH2]6NH2

C18H35NO9 (409.2312)


   

2-aminoethyl [2-hydroxy-3-[(Z)-tetradec-9-enoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(Z)-tetradec-9-enoxy]propyl] hydrogen phosphate

C19H40NO6P (409.2593)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-tridec-9-enoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-tridec-9-enoate

C18H36NO7P (409.2229)


   

CerP 17:0;2O/2:0

CerP 17:0;2O/2:0

C19H40NO6P (409.2593)


   

alpha-(4-Dimethylaminophenyl)-omega-(9-phenanthryl)octane

alpha-(4-Dimethylaminophenyl)-omega-(9-phenanthryl)octane

C30H35N (409.2769)


   

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C18H38N2O6P+ (409.2467)


   

2-[[(E)-2-(butanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(butanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C18H38N2O6P+ (409.2467)


   

2-[[(E)-2-acetamido-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-acetamido-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C18H38N2O6P+ (409.2467)


   

2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C18H38N2O6P+ (409.2467)


   

3-N-Methylspiperone

3-N-Methylspiperone

C24H28FN3O2 (409.2165)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

2-({4-[5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl}amino)ethan-1-ol

2-({4-[5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl}amino)ethan-1-ol

C23H27N3O4 (409.2001)


   

Met-Leu-Phe acetate salt

Met-Leu-Phe acetate salt

C20H31N3O4S (409.2035)


   

deacetylpyripyropene E

deacetylpyripyropene E

C25H31NO4 (409.2253)


An organic heterotetracyclic compound that is (3S,4aR,6aR,12aR,12bS)-3-hydroxy-4,4,6a,12b-tetramethyl-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-11-one substituted by a pyridin-3-yl group at position 9 (the 3S,4aR,6aR,12aR,12bS stereoisomer).

   

N-deethylaconine

N-deethylaconine

C22H35NO6 (409.2464)


A diterpene alkaloid with formula C22H35NO6, originally isolated from Aconitum carmichaeli.

   

NA-2AAA 17:2(9Z,12Z)

NA-2AAA 17:2(9Z,12Z)

C23H39NO5 (409.2828)


   

NA-Cys 20:3(8Z,11Z,14Z)

NA-Cys 20:3(8Z,11Z,14Z)

C23H39NO3S (409.2651)


   

NA-Glu 18:2(9E,12E)

NA-Glu 18:2(9E,12E)

C23H39NO5 (409.2828)


   

NA-Glu 18:2(9Z,12Z)

NA-Glu 18:2(9Z,12Z)

C23H39NO5 (409.2828)


   

NA-Met 18:3(6Z,9Z,12Z)

NA-Met 18:3(6Z,9Z,12Z)

C23H39NO3S (409.2651)


   

NA-Met 18:3(9Z,12Z,15Z)

NA-Met 18:3(9Z,12Z,15Z)

C23H39NO3S (409.2651)


   

NA-Taurine 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Taurine 20:5(5Z,8Z,11Z,14Z,17Z)

C22H35NO4S (409.2287)


   
   
   
   
   
   

LPE P-14:0 or LPE O-14:1

LPE P-14:0 or LPE O-14:1

C19H40NO6P (409.2593)


   
   

ST 19:2;O5;Gly

ST 19:2;O5;Gly

C21H31NO7 (409.21)


   

ST 20:1;O4;Gly

ST 20:1;O4;Gly

C22H35NO6 (409.2464)


   

ST 21:0;O3;Gly

ST 21:0;O3;Gly

C23H39NO5 (409.2828)


   

ST 23:6;O2;Gly

ST 23:6;O2;Gly

C25H31NO4 (409.2253)


   

4-PPBP (maleate)

4-PPBP (maleate)

C25H31NO4 (409.2253)


4-PPBP maleate is a potent σ 1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection[1][2][3].

   

16-acetyl-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

16-acetyl-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C24H31N3O3 (409.2365)


   

(2s)-2-[(2s)-n,4-dimethyl-2-(methylamino)pentanamido]-3-phenyl-n-(2-phenylethyl)propanimidic acid

(2s)-2-[(2s)-n,4-dimethyl-2-(methylamino)pentanamido]-3-phenyl-n-(2-phenylethyl)propanimidic acid

C25H35N3O2 (409.2729)


   

(1r,4s,7s,9r)-6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1r,4s,7s,9r)-6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C24H31N3O3 (409.2365)


   

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,7-dihydroxy-5-methoxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,7-dihydroxy-5-methoxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

C22H35NO6 (409.2464)


   

4',6'-dihydroxy-11'-(1-hydroxypropyl)-3-methoxy-3',4-dimethyl-10'-azaspiro[furan-2,5'-tricyclo[8.4.0.0²,⁶]tetradecan]-5-one

4',6'-dihydroxy-11'-(1-hydroxypropyl)-3-methoxy-3',4-dimethyl-10'-azaspiro[furan-2,5'-tricyclo[8.4.0.0²,⁶]tetradecan]-5-one

C22H35NO6 (409.2464)


   

3-methoxy-5'-methyl-5-(1h-pyrrol-2-yl)-3,4-dihydro-4'-oxa-18'-azaspiro[pyrrole-2,3'-tricyclo[13.2.1.0²,⁷]octadecane]-1'(17'),15'-diene

3-methoxy-5'-methyl-5-(1h-pyrrol-2-yl)-3,4-dihydro-4'-oxa-18'-azaspiro[pyrrole-2,3'-tricyclo[13.2.1.0²,⁷]octadecane]-1'(17'),15'-diene

C25H35N3O2 (409.2729)


   

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,4,8,9,16-pentol

11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,4,8,9,16-pentol

C22H35NO6 (409.2464)


   

(6r,7r,17s,18r)-3,14-dimethoxy-4,6,7,15,17,18-hexamethyl-8,11,19-trioxapentacyclo[10.7.1.0²,¹⁰.0⁵,⁹.0¹⁶,²⁰]icosa-2,4,9,12(20),13,15-hexaen-1-yl

(6r,7r,17s,18r)-3,14-dimethoxy-4,6,7,15,17,18-hexamethyl-8,11,19-trioxapentacyclo[10.7.1.0²,¹⁰.0⁵,⁹.0¹⁶,²⁰]icosa-2,4,9,12(20),13,15-hexaen-1-yl

C25H29O5 (409.2015)


   

n-[2-(4-{[(2e,4r)-5-[(2s)-3,3-dimethyloxiran-2-yl]-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

n-[2-(4-{[(2e,4r)-5-[(2s)-3,3-dimethyloxiran-2-yl]-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

C25H31NO4 (409.2253)


   

(1r,2s,3s,4s,5s,6s,8s,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,4,8,9,16-pentol

(1r,2s,3s,4s,5s,6s,8s,9r,10s,13r,16s,17r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,4,8,9,16-pentol

C22H35NO6 (409.2464)


   

(4e,7s)-n-{2-[(4r,5r)-4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl]-2-methoxyethyl}-7-methoxydodec-4-enimidic acid

(4e,7s)-n-{2-[(4r,5r)-4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl]-2-methoxyethyl}-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

(1s,2r,3r,4s,5s,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

(1s,2r,3r,4s,5s,6s,8r,9r,10s,13s,16s,17r)-11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO6 (409.2464)


   

6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl 2-methylbutanoate

6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl 2-methylbutanoate

C21H31NO7 (409.21)


   

3-[(1r,3as,5ar,9ar,9br,11as)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxypyrrol-2-one

3-[(1r,3as,5ar,9ar,9br,11as)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxypyrrol-2-one

C26H35NO3 (409.2617)


   

n-{5'-hydroxy-5-methoxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4'-yl}dodec-2-enimidic acid

n-{5'-hydroxy-5-methoxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4'-yl}dodec-2-enimidic acid

C22H35NO6 (409.2464)


   

n-[2-(4-{[5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

n-[2-(4-{[5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

C25H31NO4 (409.2253)


   

n-[2-(4-{[(2e)-5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

n-[2-(4-{[(2e)-5-(3,3-dimethyloxiran-2-yl)-4-hydroxy-3-methylpent-2-en-1-yl]oxy}phenyl)ethyl]benzenecarboximidic acid

C25H31NO4 (409.2253)


   

(1r,4s,7s,9r)-16-acetyl-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1r,4s,7s,9r)-16-acetyl-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C24H31N3O3 (409.2365)


   

(1s,2r,3r,4s,5s,6s,8r,9s,10s,13r,16s,17r,18r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16,18-pentol

(1s,2r,3r,4s,5s,6s,8r,9s,10s,13r,16s,17r,18r)-11-ethyl-6-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16,18-pentol

C22H35NO6 (409.2464)


   

(2e)-7-oxo-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

(2e)-7-oxo-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

C21H31NO7 (409.21)


   

(2r,2's,3s,5's,7's)-3-methoxy-5'-methyl-5-(1h-pyrrol-2-yl)-3,4-dihydro-4'-oxa-18'-azaspiro[pyrrole-2,3'-tricyclo[13.2.1.0²,⁷]octadecane]-1'(17'),15'-diene

(2r,2's,3s,5's,7's)-3-methoxy-5'-methyl-5-(1h-pyrrol-2-yl)-3,4-dihydro-4'-oxa-18'-azaspiro[pyrrole-2,3'-tricyclo[13.2.1.0²,⁷]octadecane]-1'(17'),15'-diene

C25H35N3O2 (409.2729)


   

(1'r,2s,2's,3'r,4'r,6'r,11's)-4',6'-dihydroxy-11'-[(1s)-1-hydroxypropyl]-3-methoxy-3',4-dimethyl-10'-azaspiro[furan-2,5'-tricyclo[8.4.0.0²,⁶]tetradecan]-5-one

(1'r,2s,2's,3'r,4'r,6'r,11's)-4',6'-dihydroxy-11'-[(1s)-1-hydroxypropyl]-3-methoxy-3',4-dimethyl-10'-azaspiro[furan-2,5'-tricyclo[8.4.0.0²,⁶]tetradecan]-5-one

C22H35NO6 (409.2464)


   

(1r,2s,3s,4s,5r,6s,8s,9s,10r,13s,16s,17s)-11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,8,13,16-tetrol

(1r,2s,3s,4s,5r,6s,8s,9s,10r,13s,16s,17s)-11-ethyl-4,6-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-3,8,13,16-tetrol

C22H35NO6 (409.2464)


   

11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

11-ethyl-13-(hydroxymethyl)-6-methoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol

C22H35NO6 (409.2464)


   

7-oxo-n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dodec-2-enimidic acid

7-oxo-n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dodec-2-enimidic acid

C21H31NO7 (409.21)


   

n-[2-(6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

n-[2-(6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

n-[2-(4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

n-[2-(4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

methyl 2-{8-hydroxy-5,7,8-trimethyl-3,9-dioxo-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-en-14-yl}acetate

methyl 2-{8-hydroxy-5,7,8-trimethyl-3,9-dioxo-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-en-14-yl}acetate

C21H31NO7 (409.21)


   

methyl (2z,4r,5s,6e)-3,5-dimethoxy-4-methyl-7-[2-(6-methylheptyl)-1,3-thiazol-4-yl]hepta-2,6-dienoate

methyl (2z,4r,5s,6e)-3,5-dimethoxy-4-methyl-7-[2-(6-methylheptyl)-1,3-thiazol-4-yl]hepta-2,6-dienoate

C22H35NO4S (409.2287)


   

(4e,7r)-n-[(2r)-2-[(1r,6r)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7r)-n-[(2r)-2-[(1r,6r)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

methyl 2-[(1r,4z,7r,8r,12s,14r,18r)-8-hydroxy-5,7,8-trimethyl-3,9-dioxo-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-en-14-yl]acetate

methyl 2-[(1r,4z,7r,8r,12s,14r,18r)-8-hydroxy-5,7,8-trimethyl-3,9-dioxo-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-en-14-yl]acetate

C21H31NO7 (409.21)


   

6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-16-propanoyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C24H31N3O3 (409.2365)


   

(4e,7s)-n-[(2s)-2-[(1s,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7s)-n-[(2s)-2-[(1s,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

n-[(1s,2s,4s,5s,6s,7r,8s)-1,7-dihydroxy-5-methoxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

n-[(1s,2s,4s,5s,6s,7r,8s)-1,7-dihydroxy-5-methoxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dodec-2-enimidic acid

C22H35NO6 (409.2464)


   

methyl (14z)-19-[(acetyloxy)methyl]-14-ethylidene-2,12,18-triazahexacyclo[9.6.1.1⁹,¹⁵.0¹,⁹.0³,⁸.0¹²,¹⁷]nonadeca-3,5,7-triene-19-carboxylate

methyl (14z)-19-[(acetyloxy)methyl]-14-ethylidene-2,12,18-triazahexacyclo[9.6.1.1⁹,¹⁵.0¹,⁹.0³,⁸.0¹²,¹⁷]nonadeca-3,5,7-triene-19-carboxylate

C23H27N3O4 (409.2001)


   

(2e)-n-[(1s,2s,4's,5s,5'r,6s)-5'-hydroxy-5-methoxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4'-yl]dodec-2-enimidic acid

(2e)-n-[(1s,2s,4's,5s,5'r,6s)-5'-hydroxy-5-methoxy-3-oxo-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-4'-yl]dodec-2-enimidic acid

C22H35NO6 (409.2464)


   

(4e,7r)-n-[(2r)-2-[(1r,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7r)-n-[(2r)-2-[(1r,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

3-{3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-hydroxypyrrol-2-one

3-{3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-hydroxypyrrol-2-one

C26H35NO3 (409.2617)